SAR445611

SAR445611 is an investigational small molecule inhibitor of receptor-interacting serine/threonine-protein kinase 1 (RIPK1), developed by Sanofi for the treatment of immune-mediated inflammatory diseases. RIPK1 is a critical signaling node that regulates pro-inflammatory cytokine production and programmed cell death, specifically necroptosis, downstream of the tumor necrosis factor (TNF) receptor. By blocking RIPK1 activity, SAR445611 aims to suppress inflammatory responses and prevent tissue damage associated with necroptotic cell death. The drug is currently being evaluated in clinical trials as a topical formulation, with a primary focus on atopic dermatitis, where localized inhibition of RIPK1 may provide therapeutic benefit while minimizing systemic exposure.